Critical roles of m6A methylation in cardiovascular diseases

Frontiers in Cardiovascular Medicine

Cardiovascular Medicine

Haichun Ma¹  Su Dong¹  Xinmin Zhang²  He Xu³  He Cai⁴ 

[1] Department of Anesthesiology, The First Hospital of Jilin University, Changchun, China;Department of Anesthesiology, The First Hospital of Jilin University, Changchun, China;The Public Laboratory Platform of the First Hospital of Jilin University, Changchun, China;Department of Integrative Medicine, Lequn Branch, The First Hospital of Jilin University, Changchun, China;The Cardiovascular Center, The First Hospital of Jilin University, Changchun, China;

关键词: cardiovascular diseases;    mA methylation;    epigenetic;    cardiac hypertrophy;    heart failure;    ischemic heart disease;    mA methylation;   

DOI  :  10.3389/fcvm.2023.1187514

 received in 2023-03-16, accepted in 2023-04-28,  发布年份 2023

来源: Frontiers

【 摘 要 】

Cardiovascular diseases (CVDs) have been established as a major cause of mortality globally. However, the exact pathogenesis remains obscure. N6-methyladenosine (m6A) methylation is the most common epigenetic modification on mRNAs regulated by methyltransferase complexes (writers), demethylase transferases (erasers) and binding proteins (readers). It is now understood that m6A is a major player in physiological and pathological cardiac processes. m6A methylation are potentially involved in many mechanisms, for instance, regulation of calcium homeostasis, endothelial function, different forms of cell death, autophagy, endoplasmic reticulum stress, macrophage response and inflammation. In this review, we will summarize the molecular functions of m6A enzymes. We mainly focus on m6A-associated mechanisms and functions in CVDs, especially in heart failure and ischemia heart disease. We will also discuss the potential application and clinical transformation of m6A modification.

【 授权许可】

Unknown   
© 2023 Zhang, Cai, Xu, Dong and Ma.